Researchers have published results from a groundbreaking clinical trial where a single dose of gene-editing treatment cured a hereditary blood disorder. The CRISPR tool was programmed to directly target and repair the mutated gene sequence in patients.
No adverse side effects were reported during the 12-month follow-up period. Regulators are now fast-tracking review processes to make this therapeutic alternative widely available next year.
